» Articles » PMID: 34452251

Polymeric Lipid Hybrid Nanoparticles (PLNs) As Emerging Drug Delivery Platform-A Comprehensive Review of Their Properties, Preparation Methods, and Therapeutic Applications

Overview
Journal Pharmaceutics
Publisher MDPI
Date 2021 Aug 28
PMID 34452251
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

Polymeric lipid hybrid nanoparticles (PLNs) are core-shell nanoparticles made up of a polymeric kernel and lipid/lipid-PEG shells that have the physical stability and biocompatibility of both polymeric nanoparticles and liposomes. PLNs have emerged as a highly potent and promising nanocarrier for a variety of biomedical uses, including drug delivery and biomedical imaging, owing to recent developments in nanomedicine. In contrast with other forms of drug delivery systems, PLNs have been regarded as seamless and stable because they are simple to prepare and exhibit excellent stability. Natural, semi-synthetic, and synthetic polymers have been used to make these nanocarriers. Due to their small scale, PLNs can be used in a number of applications, including anticancer therapy, gene delivery, vaccine delivery, and bioimaging. These nanoparticles are also self-assembled in a reproducible and predictable manner using a single or two-step nanoprecipitation process, making them significantly scalable. All of these positive attributes therefore make PLNs an attractive nanocarrier to study. This review delves into the fundamentals and applications of PLNs as well as their formulation parameters, several drug delivery strategies, and recent advancements in clinical trials, giving a comprehensive insight into the pharmacokinetic and biopharmaceutical aspects of these hybrid nanoparticles.

Citing Articles

Revolutionizing immunization: a comprehensive review of mRNA vaccine technology and applications.

Leong K, Tham S, Poh C Virol J. 2025; 22(1):71.

PMID: 40075519 PMC: 11900334. DOI: 10.1186/s12985-025-02645-6.


Oral Administration of Neratinib Maleate-Loaded Lipid-Polymer Hybrid Nanoparticles: Optimization, Physical Characterization, and In Vivo Evaluation.

Mahajan R, Ravi P, Jadhav S, Pansuriya P, Naik B, Anture S Pharmaceutics. 2025; 17(2).

PMID: 40006588 PMC: 11858839. DOI: 10.3390/pharmaceutics17020221.


Biodegradable and Stimuli-Responsive Nanomaterials for Targeted Drug Delivery in Autoimmune Diseases.

Parvin N, Joo S, Mandal T J Funct Biomater. 2025; 16(1).

PMID: 39852580 PMC: 11766201. DOI: 10.3390/jfb16010024.


Exploring the landscape of Lipid Nanoparticles (LNPs): A comprehensive review of LNPs types and biological sources of lipids.

Alfutaimani A, Alharbi N, Alahmari A, Alqabbani A, Aldayel A Int J Pharm X. 2024; 8:100305.

PMID: 39669003 PMC: 11635012. DOI: 10.1016/j.ijpx.2024.100305.


Polymer lipid hybrid nanoparticles for phytochemical delivery: challenges, progress, and future prospects.

Rahat I, Yadav P, Singhal A, Fareed M, Purushothaman J, Aslam M Beilstein J Nanotechnol. 2024; 15:1473-1497.

PMID: 39600519 PMC: 11590012. DOI: 10.3762/bjnano.15.118.


References
1.
Lian T, Ho R . Trends and developments in liposome drug delivery systems. J Pharm Sci. 2001; 90(6):667-80. DOI: 10.1002/jps.1023. View

2.
Dahmash E, Al-Khattawi A, Iyire A, Al-Yami H, Dennison T, Mohammed A . Quality by Design (QbD) based process optimisation to develop functionalised particles with modified release properties using novel dry particle coating technique. PLoS One. 2018; 13(11):e0206651. PMC: 6211725. DOI: 10.1371/journal.pone.0206651. View

3.
Lasic D, Ceh B, Stuart M, Guo L, Frederik P, Barenholz Y . Transmembrane gradient driven phase transitions within vesicles: lessons for drug delivery. Biochim Biophys Acta. 1995; 1239(2):145-56. DOI: 10.1016/0005-2736(95)00159-z. View

4.
Moghimi S, Szebeni J . Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res. 2003; 42(6):463-78. DOI: 10.1016/s0163-7827(03)00033-x. View

5.
Richter A, Waterfield E, Jain A, Canaan A, Allison B, LEVY J . Liposomal delivery of a photosensitizer, benzoporphyrin derivative monoacid ring A (BPD), to tumor tissue in a mouse tumor model. Photochem Photobiol. 1993; 57(6):1000-6. DOI: 10.1111/j.1751-1097.1993.tb02962.x. View